WHO ICTRP trial
A clinical trial to study the safety and efficacy of ALD518 in patients with…
CTRI/2009/091/000016 · Clinical Trials Registry India (CTRI) · Not Recruiting
Key facts
| Trial ID | CTRI/2009/091/000016 |
|---|---|
| Public title | A clinical trial to study the safety and efficacy of ALD518 in patients with non-small cell lung cancer-related fatigue and cachexia. |
| Scientific title | A phase II study to determine the safety, efficacy, and pharmacokinetics of multiple intravenous doses of ald518 80 mg, 160 mg, and 320 mg versus placebo administered to patients with non-small cell lung cancer-related fatigue and cachexia. |
| Primary sponsor | Alder Biopharmaceuticals Inc |
| Secondary sponsors | Veeda Clinical Research Pvt Ltd |
| Registry | Clinical Trials Registry India (CTRI) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase 2 |
| Countries | India |
| Conditions | Health Condition 1: J988- Other specified respiratory disorders |
| Interventions | Intervention1: ALD518: Group A: ALD518 80 mg every 8 weeks (3 doses) Group B: ALD518 160 mg every 8 weeks (3 doses) Group C: ALD518 320 mg every 8 weeks (3 doses) Control Intervention1: Placebo: Group D: Placebo every 8 weeks (3 doses) |
| Registration date | Jan 16, 2009 |
| Target size | 0 |
| Registry page | ctri.nic.in |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: